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Abstract
Objective To examine the prevalence and patterns of high risk
prescribing, defined as potentially inappropriate prescribing of drugs to
primary care patients particularly vulnerable to adverse drug events.
Design Cross sectional population database analysis.
Setting General practices in Scotland.
Participants 315 Scottish general practices with 1.76 million registered
patients, 139 404 (7.9%) of whomwere defined as particularly vulnerable
to adverse drug events because of age, comorbidity, or co-prescription.
Main outcomemeasuresHow reliably each of 15 indicators—four each
for non-steroidal anti-inflammatory drugs, co-prescription with warfarin,
and prescribing in heart failure, two for dose instructions for methotrexate,
and one for antipsychotic prescribing in dementia—and a composite of
all 15 could distinguish practices in terms of their rates of high risk
prescribing; and characteristics of patients and practices associated with
high risk prescribing in a multilevel model.
Results 19 308 of 139 404 (13.9%, 95% confidence interval 13.7% to
14.0%) patients had received at least one high risk prescription in the
past year. This composite indicator was a reasonably reliable measure
of practice rates of high risk prescribing (reliability >0.7 for 95.6% of
practices, >0.8 for 88.2%). The patient characteristic most strongly
associated with high risk prescribing was the number of drugs prescribed
(>11 long term prescribed drugs v 0; odds ratio 7.90, 95% confidence
interval 7.19 to 8.68). After adjustment for patient characteristics, rates
of high risk prescribing varied by fourfold between practices, which was
not explained by structural characteristics of the practices.
Conclusions Almost 14% of patients defined as particularly vulnerable
to adverse drug events were prescribed one or more high risk drugs.
The composite indicator of high risk prescribing used could identify
practices as having above average or below average high risk prescribing
rates with reasonable confidence. After adjustment, only the number of
drugs prescribed long term to patients was strongly associated with high
risk prescribing, and considerable unexplained variation existed between
practices. High risk prescribing will often be appropriate, but the large
variation between practices suggests opportunities for improvement.
Introduction
Improving the safety of patients is an increasing priority for
health policy and health services. Much work has focused on
care in hospital, with less attention to major sources of harm in
primary care, such as prescribing. Good evidence shows that
prescribing in primary care causes considerable harm. Adverse
drug events account for 6.5% of all hospital admissions,1 over
half of which are judged to be preventable.2Themost commonly
implicated drug classes are antiplatelet drugs, including aspirin,
diuretics, non-steroidal anti-inflammatory drugs (NSAIDs),
warfarin, opioids, β blockers, and angiotensin converting
enzyme inhibitors/angiotensin receptor blockers.2 Deaths from
adverse drug events are most often associated with NSAIDs
and prescribing of antiplatelets.1 Several national safety alerts
have also been created for less commonly prescribed drugs
implicated in preventable deaths. Examples include guidance
on the prescribing and monitoring of methotrexate3 and
antipsychotic use in older people with dementia.4
Although treatment in the United Kingdom may start in both
primary and secondary care, general practitioners carry out
almost all of the prescribing driving these admissions, as they
prescribe virtually all drugs in the community and are
responsible for drug reviews. However, few data exist on how
common high risk prescribing is in primary care or how it varies
between patients and between practices. For example, despite
rapid changes in policy on antipsychotic use in older people
with dementia,4 5 few population based studies have been carried
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out on rates of such prescribing6 and most have been small and
usually based in nursing homes.5
Although there are several measures of potentially inappropriate
prescribing, the Beers criteria are the ones most commonly used.
These criteria consist of two drug lists: one of drugs that are
potentially inappropriate in elderly people, such as long acting
benzodiazepines, and another of drugs that may be inappropriate
in elderly people with particular conditions, such as
anticholinergics in chronic constipation.7 The Beers criteria can
be assessed relatively easily in routine healthcare data and have
been widely applied as a result, but most of the drugs listed are
rarely used and the list does not include many of the drugs most
associated with serious harm or with emergency hospital
admission. More recently developed tools include drug items
in the Assessing Care of Vulnerable Elders project8 and the
screening tool of older persons potentially inappropriate
prescriptions (STOPP). The screening tool is better associated
with harm in older people admitted to hospital than are the Beers
criteria, but both tools require record review to implement,
precluding large scale or routine use.9 10
We examined the frequency of high risk prescribing in patients
particularly vulnerable to adverse drug events, how reliably the
indicators could distinguish between practices (which is critical
if indicators are to be used to measure practices for high stakes
evaluation, including performance management and clinical
governance), and patient and practice characteristics associated
with high risk prescribing.
Methods
Using the dataset held by the Primary Care Clinical Information
Unit at the University of Aberdeen, we extracted data from 315
general practices in Scotland contributing to the Scottish
programme for improving clinical effectiveness in primary care
(SPICE-PC), with analysis based on complete data as at 31
March 2007. Thirty one per cent of Scottish practices contributed
data, covering a population representative of Scotland for age,
sex, and deprivation, and including patients living in their own
homes or in nursing homes.11
Population
We extracted data for all patients permanently registered on 31
March 2007 who were defined as being particularly vulnerable
to one of the specified prescriptions because of age, pre-existing
disease (heart failure, dementia, chronic kidney disease, peptic
ulcer), or pre-existing co-prescription (warfarin, angiotensin
converting enzyme inhibitor, angiotensin receptor blocker,
diuretic). We used the disease register business rules of the UK
Quality and Outcomes Framework to define heart failure,
chronic kidney disease, dementia, and psychosis, with a bespoke
Read code set used to define peptic ulcer disease.12
For each patient we also extracted data on age; sex; postcode
assigned deprivation, using the Carstairs score (grouped into
fifths)13; and number of oral drugs on active repeat prescription,
with at least one prescription issued in the past 84 days.
Variables defined at practice level were rurality or remoteness
based on the Scottish Executive urban-rural classification, list
size (grouped into fourths), whether the practice held a new
General Medical Services or section 17c or 2c contract (the
Scottish equivalent of a Personal Medical Services contract
where there is local variation from the national new General
Medical Services template), postgraduate training status,
dispensing status, whether the practice was single handed, and
whether the practice achievedmaximum points for three relevant
drug measures in the Quality and Outcomes Framework:
medicines 10, where practices are paid for meeting prescribing
advisers and agreeing three improvement projects for the
subsequent year, with evidence of delivery of the previous year’s
agreed projects, and medicines 11 and 12 where practices are
paid for carrying out drug reviews on more than 80% of patients
taking repeat drugs, with extra payment for achieving this for
patients taking four or more repeat drugs.12
Outcome definition
Given the limitations of existing indicator sets described above,
we defined a new set of indicators of hazardous prescribing for
drugs prescribed in situations identified as clearly high risk in
national safety alerts3-14 and commonly implicated in serious
harm, as measured by emergency hospital admission due to an
adverse drug event.1 2 Indicators were required to be ones where
the prescribing being measured was clearly stated to be
contraindicated or to be avoided in routine practice, either in
the British National Formulary,15 national clinical guidelines,16
prescribing advice,14-19 or safety alerts.3 It is important to
recognise that most patients receiving such prescriptions will
not be harmed and few of these prescriptions are absolutely
contraindicated. However, for every indicator examined there
was explicit guidance at the time of prescription that it carried
significant risk of harm and should be routinely avoided, usually
on the basis of clear evidence that such prescribing carried a
significantly increased risk to patients. Candidate indicators
were rated in a modified RAND process20 involving a panel of
four general practitioners (two with roles in improving
prescribing at primary care organisation level) and six
pharmacists (two with an academic interest in safe prescribing,
the remainder with pharmacy roles in both primary care
organisation and hands-on practice). Included indicators were
all rated as “necessary to avoid” (median score >7 on a 9 point
scale, with no disagreement within the panel20). Indicators were
additionally required to be measureable using routine electronic
clinical data in primary care, which precluded those based on
laboratory monitoring that is inconsistently recorded in general
practice records. Notably, we excluded indicators related to
warfarin and hypoglycaemic drug monitoring.
The outcomes measured were receipt of a drug defined as high
risk prescribing for a patient because of their age, a pre-existing
condition, or they were already prescribed drugs that could
potentially interact with the ones being prescribed. The period
over which receipt of a drug was measured varied from the past
12 weeks for co-prescription and dose instructions for
methotrexate to one year for prescription to people defined as
vulnerable to adverse drug events because of age or comorbidity.
We defined 15 individual indicators (table 1). For each indicator
we extracted details of relevant drug prescribing recorded in
the electronic record in the year from 1 April 2006 to 31 March
2007. Drug definitions used codes from the British National
Formulary supplemented with free text name searches where
necessary. For example, for the measure
“Risperidone/olanzapine prescribed in over-65s with dementia
but not psychosis,” we included patients if their electronic record
had a relevant Read code for the presence of dementia
(excluding those with a Read code for the presence of psychosis
or serious mental illness, as defined by the Quality and
Outcomes Framework, where a prescription for antipsychotics
is more clearly indicated). We then measured the proportion of
such patients with an electronic record of prescription for
risperidone or olanzapine in the 12 weeks before 31 March
2007. In addition, an overall composite indicator was also
defined as whether or not the patient had received any high risk
prescription.
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Statistical analysis
For each indicator we calculated the proportion of patients
receiving a high risk prescription, with 95% confidence intervals.
We also determined the reliability of indicators in distinguishing
between practices. Reliability in this context refers to how
accurately an indicator measures an individual practice’s
performance based on a mean score of a patient level outcome.
It is therefore a measure of how confident we can be that
observed differences between practices result from true
differences in prescribing safety.29 Reliability increases as
variation between practices increases (measured by the
intracluster correlation coefficient, which is estimated using all
the data and is the same for all practices) and as the number of
patients being measured in the practice increases. An indicator
may therefore be reliable for a large practice but not for a small
one. For an indicator to be used routinely to compare practices
for performancemanagement or governance purposes, it requires
adequate reliability for as many of the practices being measured
as possible. Reliability varies between 0 (completely unreliable)
and 1 (completely reliable). Values greater than 0.7 are generally
considered to indicate acceptable reliability in the sense that
observed differences between practices can be reasonably
confidently attributed to true differences in quality or safety.
For high stakes evaluation, reliabilities of 0.8-0.9 are
preferable.29-31
We estimated the intracluster correlation coefficient for each
indicator in an empty multilevel logistic regression model, and
the reliability of each indicator and the composite calculated
using the Spearman-Brown prophecy formula for a notional
practice, with the median number of patients being measured
by the indicator. Based on the actual number of patients being
measured in each practice, for each indicator we additionally
calculated the proportion of practices with reliability of greater
than 0.7 and greater than 0.8.30 31
We used multilevel logistic regression to examine how the
composite indicator of receipt of at least one high risk
prescription varied between practices and by patient and practice
characteristics. For patient and practice variables we calculated
multilevel univariate odds ratios. Two multivariate (adjusted)
models were estimated, with patient level variables fitted first
and variables retained based on statistical significance using a
Wald test. For both models we estimated the explained variance
(R2).32We examined variation between practices after controlling
for differences in case mix by plotting on a cross sectional
control chart the observed versus expected numbers of patients
with a high risk prescription.33A sensitivity analysis was carried
out to examine whether dropping the least reliable individual
indicators improved the composite reliability or changed the
overall conclusions frommultilevel regression. All models were
fitted with second order penalised quasi-likelihood estimation,
and assumptions of normality of level 2 residuals and other
model diagnostics checked graphically. Initial analysis was
carried out in SPSS v17.0, and multilevel logistic regression in
MlWin 2.0 (Centre for Multilevel Modelling, University of
Bristol, UK).
Results
Overall, 139 404 of 1 760 223 (7.92%, 95% confidence interval
7.88% to 8.00%) patients were defined as being particularly
vulnerable to adverse drug events because of their age,
pre-existing disease, or co-prescription. Table 2 shows the rate
of high risk prescribing for each of the indicators, which varied
from 0.5% to 50.5%. In total, 19.7% (95% confidence interval
19.1% to 20.3%) of patients prescribed warfarin had received
a high risk prescription in the past year (most commonly for
antiplatelets or high risk antibiotics), and 18.2% (17.6% to
18.7%) of patients with heart failure had been prescribed a drug
that was contraindicated or recommended to be avoided (most
commonly NSAIDs or tricyclics). Other high risk prescribing
of NSAIDswas also relatively common, with rates ranging from
4.1% of older people with renal impairment to 50.5% of over
75s prescribed an NSAID without gastroprotection. Most
patients prescribed an NSAID had received multiple
prescriptions for these drugs in the previous year. In total, 19
308 of the 139 404 patients particularly vulnerable to adverse
drug events (13.9%, 95% confidence interval 13.7% to 14.0%)
had received at least one high risk prescription in the past year.
Overall, 16 423 (84.1% of those receiving any high risk drug)
patients received only one type of high risk prescription, 2530
(13.1%) two, and 546 (2.8%) three or more.
Reliability of indicators in distinguishing
between practices
Variation between practices in the overall rate of high risk
prescribing measured by the composite was considerable,
ranging from 3.6% of patients receiving at least one high risk
prescription to 31.3% (median 12.5%, interquartile range
10.1-15.3%). Twelve of the 15 indicators (excluding the warfarin
and heart failure composites) had adequate reliability (>0.7) for
a median sized practice, but significant numbers of practices
had too few patients to be reliably measured. Depending on the
indicator, between 31.7% and 91.7% of practices had reliability
greater than 0.7, and between 7.6% and 80.3% had reliability
greater than 0.8. The reliability of the composite for a median
sized practice was 0.92, with reliability greater than 0.7 in 95.6%
of practices and greater than 0.8 in 88.2%.
Patient and practice characteristics
associated with high risk prescribing
Table 3 shows the percentage of patients receiving at least one
high risk prescription by a range of patient and practice
characteristics, and univariate odds ratios estimated in a
multilevel model. High risk prescribing increased noticeably
with the number of drugs recently issued on a repeat
prescription, with 4.3% of patients with no long term prescribed
drugs receiving a high risk prescription compared with 26.6%
of those prescribed 11 or more drugs long term (difference in
proportions 22.2%, 95% confidence interval 21.1% to 23.3%).
High risk prescribing also increased with age, rising
progressively from 6.7% in the under 40s to 15.9% in 70-79
year olds, but decreasing to 13.2% in those aged 80 and over
(difference for age <40 v 70-79 9.2%, 95% confidence interval
8.3% to 10.1%). Other patient level variables had smaller
associations, although still statistically significant.Womenwere
more likely to receive a high risk prescription (14.6% v 13.1%
in men, difference 1.5%, 1.1% to 1.8%) as were patients living
in more socioeconomically deprived areas (15.3% v 12.8% for
those living in the most affluent areas, difference 2.5%, 1.9%
to 3.1%). High risk prescribing varied less by practice level
variables, with higher rates in smaller practices compared with
large practices, in non-training practices, and in practices with
a section 2c or 17c (Personal Medical Services) contract.
In the multivariate model including only patient level variables
(table 4, model 1), the association of high risk prescribing with
the number of active repeat drugs was largely unchanged.
Associations with age and sex were weaker in the adjusted
model and, although statistically significant, were small in
absolute terms. Associations with deprivation were found to be
no longer significant. The patient level variables in model 1
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explained 8.1% of the variance in receipt of a high risk
prescription. Three practice variables were significantly
associated with high risk prescribing in the adjustedmodel (table
4, model 2). Compared with smaller practices (list size <4675),
patients in the largest practices (list size >9876) were less likely
to receive a high risk prescription. Patients in non-training
practices were more likely to receive a high risk prescription as
were patients in urban and accessible areas compared with
primary cities. However, the absolute differences and the
adjusted odds ratios were all small, and adding practice variables
only explained an additional 0.5% of the variance in receipt of
a high risk prescription (R2=8.6% for model 2 v 8.1% for model
1).
Variation between practices was considerable even after
adjusting for case mix in terms of the patient level variables in
model 1. The figure shows how the observed numbers of patients
with a high risk prescription differed from expected in each
practice after adjustment for patient case mix. Practices lying
outside the 3 standard deviation control limit were statistically
significantly different from the average, and varied from having
half the expected rates of high risk prescribing to having a
50-125% excess. The median odds ratio for two patients
randomly selected from different practices was 1.42 (95%
confidence interval 1.37 to 1.47).34
In the sensitivity analysis, reanalysing the data after dropping
the three least reliable indicators (prescribing NSAIDs to older
patients without gastroprotection, prescribing mixed strengths
of methotrexate, and prescribing high risk antibiotics to patients
taking warfarin) did not substantively alter the findings or their
interpretation. The reliability of the 12 indicator composite was
0.92 for the median sized practice, and reliability was greater
than 0.7 for 94.9% of practices and greater than 0.8 for 87.6%
(sensitivity analysis multilevel modelling data not shown).
Discussion
As measured by the 15 indicators examined, high risk
prescribing is relatively common, with 13.9% of patients
particularly vulnerable to adverse drug events receiving one or
more high risk prescriptions in the past year. Although individual
indicators did not reliably distinguish practices, the composite
indicator of whether or not patients had received one or more
high risk prescriptions in the past year was reasonably reliable,
with 95.6% of practices having greater than 0.7 reliability and
88.2% greater than 0.8. The implication is that we can be
reasonably confident that the composite indicator correctly
defines practices as having above average or below average
rates of high risk prescribing (whereas we cannot be confident
that the individual indicators do so).
In multilevel logistic regression analysis, only the number of
drugs the patient was being prescribed long term was strongly
associated with high risk prescribing, but considerable
unexplained variation existed between practices. Although
several other patient level and practice level variables were
statistically significantly associated with receipt of a high risk
prescription, the odds ratios for these were close to one in the
adjusted model, and the clinical significance of these
associations is marginal. Notably, after adjustment for patient
level variables, patients in the lowest prevalence practices had
about half the expected rate of high risk prescribing, whereas
the highest prevalence practices had 50-125% more patients
with high risk prescribing than expected (figure). This variation
at practice level was not explained by the structural
characteristics of the practices included in the model, and in
particular was not associated with performance measured by
the three Quality and Outcomes Framework management
indicators for medicines that we examined.12
Strengths and weaknesses of the study
To our knowledge, this is the first large scale study of
prescribing safety in primary medical care that uses multiple
indicators based on explicit national prescribing safety advice,
and examines how high-risk prescribing varies between both
patients and practices in a highly representative population. The
study has several important limitations. Firstly, although the
prescribing being measured is defined as high risk in national
guidance, it is not always inappropriate. This is because real
life prescribing often involves balancing risk and benefit in
conditions of uncertainty, and a drug may be high risk but still
a rational and reasonable one to prescribe. Unlike situations
such as the surgical excision of a healthy right sided kidney
instead of a diseased left sided one, few of these indicators are
therefore measuring “never events” where the care given is
unequivocally wrong.35 However, given that all the prescribing
examined is stated in national guidance to be contraindicated
or to be avoided in routine practice, the high rates and large
variation between practices is consistent with a significantly
appropriate proportion of prescribing examined.
Secondly, because of constraints on feasibility, the indicators
used represent only a selection of possible important measures.
For example, although both warfarin and hypoglycaemic drugs
contribute significantly to emergency hospital admission with
adverse drug events,1 2 variable recording of laboratory data
meant that we could not include indicators relating to warfarin
monitoring in this analysis, and indicators for safe use of
hypoglycaemic drugs in diabetes were not feasible. The indicator
set is therefore not comprehensive, reflecting the difficulty in
capturing the full complexity of prescribing electronically.
Additionally, over the counter purchase of ibuprofen from
pharmacies is not recorded electronically in general practice
clinical systems. This study is therefore likely to significantly
under-estimate the true rate of high risk prescribing by general
practitioners and wider use of high risk medicines.
Thirdly, variation between practices may be due to unmeasured
heterogeneity in case mix, such as varying comorbidity
(although this is likely to be significantly accounted for by the
variable relating to the number of drugs prescribed long term).
Finally, although the study identified significant variation in
high risk prescribing between practices, it did not examine
variation between individual doctors within the practices. The
study therefore could not distinguish between practices with
generalised high risk prescribing and practices with individual
prescribers who are higher than average risk. Both are likely to
be important. If high risk prescribing was largely driven by
individuals, however, it seems likely that practice list size would
be a stronger predictor, since individual effects should be
progressively diluted in larger practices.
Unanswered questions and future research
Several areas of uncertainty would benefit from further research.
The first relates to validity, or the degree to which an indicator
measures what it claims to, in this case high risk prescribing.
The indicators examined have strong face validity because they
are all subject to explicit national guidance, and most are
underpinned by a strong evidence base that quantifies the risk
involved. For example, the current evidence from randomised
controlled trials is that treating 100 people with dementia with
an antipsychotic for 6-12 weeks is associated with one additional
death. It is estimated that prescribing of antipsychotics in people
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with dementia is associated with 1620 additional strokes (half
severe) and 1800 additional deaths per year in the United
Kingdom. This might be acceptable if antipsychotics had large
benefits in this population, but they do not.5 14 However, the
evidence base underlying some other indicators is weaker, which
makes explicit consideration of risks and benefits of a particular
drug to an individual difficult. For example, the significant risk
of co-prescribing antiplatelet drugs andNSAIDs to people taking
warfarin is well quantified.21-23 Yet despite the toxicity of
warfarin and the frequency with which it is prescribed, there
are few precise estimates of the risk of other co-prescribed drugs,
including antibiotics.21 The growth of large, linkable electronic
databases should allow more systematic study of the risks of
prescribing in primary care in the future. Further evidence of
validity would come from intervention studies showing that
rates of high risk prescribing can be reduced, and ideally that
patient harm is reduced as a result.
Secondly, although this study identified that high risk
prescribing varied considerably between practices, none of the
practice level variables examined accounted for this variation.
Potentially useful areas to explore are whether practice rates of
high risk prescribing are driven more by a small number of
individual prescribers or are more strongly related to wider
practice organisation and culture of prescribing safety.36 Both
are likely to contribute, but practice culture and organisation
are likely to be important because clinical care and responsibility
for generating, checking, and signing repeat prescriptions is
almost always shared. Further work is therefore required to
understand better the sources of variation between practices,
and an additional priority is to rigorously develop and test
interventions targeting individuals or practices.37
Thirdly, research is needed to understand better and improve
existing mechanisms for making prescribing safer. From this
perspective, the most effective way to implement drug alerts in
general practice clinical IT systems is uncertain. The data
examined here came from a system in which drug interaction
alerts were routine, were tiered (using a traffic light system to
flag more serious interactions), and were non-interruptive (alerts
are advisory and do not require the prescriber to explicitly
over-ride them). Other IT systems also include drug-disease
warnings38 and vary in tiering and whether prescribers have to
over-ride alerts. A need exists for comparison of high risk
prescribing rates in practices using different prescribing decision
support systems. However, such alerts only trigger when a drug
is newly prescribed, which means that patients receiving high
risk drugs authorised for repeat prescribing are not explicitly
flagged during subsequent drug review. The Quality and
Outcomes Framework includes incentives for carrying out drug
reviews for such patients, but there is little guidance as to the
content of such reviews,12 and in this study it is notable that
there was no relation between high risk prescribing and
achieving maximum Quality and Outcomes Framework points
for the three drug review and medicines improvement activity
measures examined. Research that examines how to make drug
review more effective is needed.
Conclusions and implications for policy and
practice
From a clinical and health services perspective, this study shows
that opportunities to improve primary care prescribing safety
are considerable. The composite indicator used in this study has
strong face validity because the indicators underlying it are all
based on national guidance, and there is strong epidemiological
evidence of harm for most indicators included. It is also a
reliable enough measure to be used to distinguish practices with
high and low rates of high risk prescribing. In principle, this
kind of composite could therefore be used for the purposes of
clinical governance and performance management—for
example, by identifying practices with particularly high rates
of high risk prescribing for further investigation.30 39
In practice major reductions in high risk prescribing are likely
to require improvement across the whole distribution of practices
to shift the average rather than solely focusing on outliers. It is
also important to recognise that not all high risk prescribing is
inappropriate, so the “correct” rate for indicators like these is
unlikely to be zero. Routine electronic data can measure rates
of high risk prescribing, but record or patient reviewwill usually
be needed to properly judge appropriateness. From a quality
improvement perspective, the best use of these indicators is
therefore likely to be to target drug review for patients receiving
high risk prescriptions, prompting the explicit application of
clinical judgment to questions of appropriateness. The findings
suggest that existing activity to improve prescribing is
insufficiently focused on safety, despite the considerable harm
caused by prescribing. This possibly reflects both the historical
background of improving prescribing by focusing on costs and
the lack of routinely available indicators of prescribing safety.
The current ubiquity of electronic data in UK primary care
makes routine measurement of the kind carried out in this study
feasible, and it is time to make prescribing safety a priority in
primary care.
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What is already known on this topic
Preventable adverse drug events related to prescribing in primary care are a common cause of hospital admission and
death
Potentially inappropriate prescribing has been shown to be relatively common using various indicator sets
Existing indicator sets do not always measure prescribing of drugs most commonly associated with harm or cannot be
applied in routine clinical data
What this study adds
14% of patients defined as particularly vulnerable to adverse drug events because of age, pre-existing disease, or
co-prescription had received a high risk prescription in the past year
High risk prescribing was much more common in patients prescribed long term drugs
Significant variation between practices was not explained by patient case mix or by a range of practice structural factors
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Tables
Table 1| Indicator definitions
Denominator definitionNumerator definitionMeasure name
No of patients with ≥1 year history of peptic ulcer
disease
No of patients prescribed oral NSAID in past year without
prescription of gastroprotective drug in eight weeks before
prescription of NSAID
NSAID prescribed in patient with peptic ulcer
without gastroprotection15 19
No of patients aged ≥75 prescribed NSAID in past
12 weeks
No of patients prescribed NSAID in past 12 weeks without
prescription of gastroprotective drug in eight weeks before
prescription of NSAID
NSAID prescribed in over 75s without
gastroprotection15 19
No of patients aged ≥65 prescribed angiotensin
converting enzyme inhibitor or angiotensin
receptor blocker and diuretic in past 12 weeks
No of patients prescribed NSAID in past 12 weeks (“triple
whammy”)
NSAID prescribed in over 65s prescribed
angiotensin converting enzyme inhibitor or
angiotensin receptor blocker and diuretic24 25
No of patients aged ≥65 with stage 3, 4, or 5 renal
impairment (estimated glomerular filtration rate
<60)
No of patients prescribed NSAID in past 12 weeksNSAID prescribed in over 65s with estimated
glomerular filtration rate <6015 26
No of patients prescribed warfarin in past 12
weeks
No of patients co-prescribed one of specified drugs in past year
while taking warfarin. Co-prescription defined as both drugs
prescribed on same day in past year, or prescription of high risk
drug between two warfarin prescriptions in past year—that is,
although measure includes only those currently taking warfarin,
co-prescription in past year has to occur while patients were
NSAID, antiplatelet, high risk antibiotic, or oral
azole antifungal prescribed to current warfarin
user15 23
receiving warfarin. High risk antibiotics defined as macrolides,
quinolones, and metronidazole
No of patients with diagnosis of heart failure
recorded at time of last prescription
No of patients prescribed at least one of specified drugs in past
year. Other “drugs to avoid” are tadalafil, disulfiram, minoxidil,
and class I and III antiarrhythmics, except amiodarone,
verapamil, diltiazem, and itraconazole
NSAID, tricyclic, thiazolidinedione, or other “drug
to avoid” prescribed to patient with heart failure16
17 27
No of patients prescribed methotrexate in past 12
weeks
No of patients without an explicitly weekly dose instruction on
last prescription
Methotrexate not prescribed with explicit
instruction to take weekly15
No of patients prescribed methotrexate in past 12
weeks
No of patients co-prescribed 10 mg and 2.5 mg methotrexate
tablets on last prescription
Methotrexate 2.5 mg and 10mg co-prescription15
No of patients aged ≥65 with diagnosis of
dementia recorded at time of last prescription but
with no diagnosis of psychosis recorded at time
of last prescription
No of patients prescribed olanzapine or risperidone in past 12
weeks
Risperidone/olanzapine* prescribed in over 65s
with dementia but not psychosis14 28
NSAID=non-steroidal anti-inflammatory drug.
*Reflects national guidance at time care was delivered. More recent guidance is that all antipsychotics are contraindicated in older people with dementia except
for risperidone for short term treatment of aggression.
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Table 2| Percentage of patients receiving high risk prescription
% of practices
with reliability
>0.8
% of practices
with reliability
>0.7
Reliability for
practice with
median
denominator size*% (95% CI)
No of patients receiving
high risk prescription/No
of patients particularly
vulnerable to ADEPrescribing safety indicator
59.777.50.848.8 (8.6 to 9.1)4371/49 574NSAID prescribed in patient with peptic ulcer
disease without gastroprotection
7.631.70.6450.5 (49.5 to 51.5)4464/8840NSAID prescribed in patients 75 and over
without gastroprotection
79.490.50.888.8 (8.5 to 9.0)3908/44 492NSAID prescribed in patients aged 65 and
over prescribed angiotensin converting
enzyme inhibitor or angiotensin receptor
blocker and diuretic
40.361.60.768.2 (7.1 to 9.3)2272/27 668NSAID prescribed in patients aged 65 and
over with estimated glomerular filtration rate
<60
72.786.00.863.4 (3.1 to 3.7)550/16 182NSAID prescribed to current warfarin user
36.866.70.769.6 (9.2 to 10.1)1554/16 182Antiplatelet prescribed to current warfarin user
13.342.20.677.9 (6.4 to 9.3)1271/16 182High risk antibiotic prescribed to current
warfarin user
29.260.30.740.7 (0.6 to 0.8)116/16 182Oral azole antifungal prescribed to current
warfarin user
33.659.40.7311.4 (11.0 to 11.9)2181/19 052NSAID prescribed to patient with heart failure
35.960.30.746.5 (6.2 to 6.9)1246/19 052Tricyclic prescribed to patient with heart failure
47.371.10.801.5 (1.3 to 1.6)278/19 052Thiazolidinedione prescribed to patient with
heart failure
80.391.70.900.5 (0.4 to 0.6)87/19 052Other “drugs to avoid” prescribed to patient
with heart failure†
36.858.10.762.6 (2.1 to 3.2)92/3487Methotrexate not prescribed with explicit
instruction to take weekly
19.045.40.6911.8 (10.7 to 12.8)410/3487Methotrexate 2.5 mg and 10 mg
co-prescription
62.276.50.842.8 (2.5 to 3.2)288/10 171Risperidone/olanzapine prescribed in over
65s with dementia but not psychosis
88.295.60.9213.9 (13.7 to 14.0)19 308/139 404Patients with at least one high risk prescription
(all indicators)
ADE=adverse drug event; NSAID=non-steroidal anti-inflammatory drug.
*Reliability coefficient can vary between 0 (completely unreliable) and 1 (completely reliable). Values greater than 0.7 are generally considered as indicating
acceptable reliability, although for high stakes evaluation, reliabilities of 0.8-0.9 are preferable.
†Other “drugs to avoid” are tadalafil, disulfiram, minoxidil, and class I and III antiarrhythmics, except amiodarone, verapamil, diltiazem, and itraconazole.
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Table 3| Percentage of patients receiving high risk prescription and multilevel univariate odds ratios of patient receiving at least one high
risk prescription
Multilevel univariate odds ratio (95% CI)% receiving any high risk prescription (95% CI)Variable
Patient level fixed effects (No of patients)
Age:
16.7 (5.9 to 7.5)<40 (3870)
1.30 (1.12 to 1.51)8.4 (7.8 to 9.0)40-49 (8108)
2.04 (1.78 to 2.34)12.6 (12.0 to 13.1)50-59 (13 242)
2.38 (2.08 to 2.71)14.4 (14.0 to 14.8)60-69 (27 238)
2.69 (2.36 to 3.06)15.9 (15.6 to 16.2)70-79 (47 663)
2.20 (1.93 to 2.51)13.2 (12.9 to 13.6)≥80 (39 283)
Sex:
113.1 (12.9 to 13.3)Male (67 204)
1.14 (1.10 to 1.17)14.6 (14.3 to 14.8)Female (72 200)
Carstairs deprivation fifth:
112.8 (12.4 to 13.2)1 (affluent) (24 392)
1.05 (0.99 to 1.12)13.0 (12.7 to 13.4)2 (30 204)
1.05 (0.98 to 1.12)14.0 (13.6 to 14.4)3 (32 033)
1.08 (1.02 to 1.16)14.1 (13.7 to 14.5)4 (26 946)
1.10 (1.03 to 1.18)15.3 (14.8 to 15.7)5 (deprived) (25 829)
No of active repeat drugs:
14.3 (4.1 to 4.7)0 (19 082)
2.68 (2.47 to 2.91)11.0 (10.5 to 11.4)1 or 2 (21 709)
3.18 (2.94 to 3.43)12.7 (12.3 to 13.1)3 or 4 (30 460)
3.69 (3.42 to 3.99)14.5 (14.1 to 14.9)5 or 6 (30 345)
4.87 (4.50 to 5.27)18.3 (17.8 to 18.8)7 or 8 (20 445)
5.92 (5.44 to 6.45)21.5 (20.7 to 22.3)9 or 10 (10 372)
7.81 (7.15 to 8.54)26.6 (25.5 to 27.6)≥11 (6991)
Practice level fixed effects (No of practices*)
List size fourth:
115.4 (14.7 to 16.0)512-4675 (79)
0.95 (0.85 to 1.07)14.8 (14.4 to 15.2)4676-7318 (79)
0.88 (0.79 to 0.99)13.9 (13.5 to 14.2)7319-9875 (79)
0.82 (0.73 to 0.92)13.2 (12.9 to 13.4)9876-21 440 (78)
Contract:
114.0 (13.8 to 14.2)New General Medical Services (270)
0.88 (0.78 to 1.00)12.3 (11.8 to 12.8)2c or 17c (Personal Medical Services) (39)
Training:
112.5 (12.2 to 12.8)Yes (105)
1.19 (1.10 to 1.28)14.9 (14.6 to 15.2)No (204)
Dispensing:
114.2 (13.6 to 14.0)No (276)
1.09 (0.94 to 1.26)13.8 (13.3 to 15.1)Yes (33)
Single handed:
113.8 (13.6 to 14.0)No (282)
1.07 (0.90 to 1.26)15.0 (13.8 to 16.2)Yes (27)
Rurality/remoteness:
112.6 (12.3 to 12.9)Primary city (111)
1.16 (1.06 to 1.28)14.6 (14.3 to 14.9)Urban area (88)
1.20 (1.07 to 1.33)14.6 (14.1 to 15.0)Accessible area (70)
1.19 (0.99 to 1.42)15.0 (14.2 to 15.7)Remote area (15)
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Table 3 (continued)
Multilevel univariate odds ratio (95% CI)% receiving any high risk prescription (95% CI)Variable
1.02 (0.89 to 1.18)13.5 (12.8 to 14.1)Very remote area (31)
Maximum QOF points for medicines 10-12:
113.7 (13.5 to 13.9)Yes (292)
1.13 (0.95 to 1.35)16.4 (15.5 to 17.3)No (17)
QOF=Quality and Outcomes Framework.
*Practice level data were unavailable for 6 (1.9%) practices with 2139 (1.5%) patients.
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Table 4| Multivariate odds ratios of patient receiving one or more high risk prescriptions
Odds ratio (95% CI)
Variable
Model 2 patient and practice level variables (309 practices, 137
265 patients*)
Model 1 patient level variables only (315 practices, 139
404 patients)
Patient level fixed effects
Age:
11<40
1.12 (0.96 to 1.30)1.12 (0.96 to 1.30)40-49
1.35 (1.18 to 1.56)1.35 (1.18 to 1.56)50-59
1.16 (1.01 to 1.33)1.16 (1.01 to 1.33)60-69
1.18 (1.03 to 1.35)1.18 (1.03 to 1.35)70-79
0.98 (0.85 to 1.12)0.98 (0.86 to 1.13)≥80
Sex:
11Male
1.05 (1.02 to 1.09)1.05 (1.02 to 1.08)Female
No of active repeat drugs:
110
2.69 (2.48 to 2.93)2.69 (2.47 to 2.92)1-2
3.25 (2.99 to 3.53)3.24 (2.99 to 3.52)3-4
3.81 (3.51 to 4.13)3.79 (3.49 to 4.11)5-6
5.01 (4.61 to 5.45)5.01 (4.61 to 5.45)7-8
6.08 (5.56 to 6.65)6.06 (5.54 to 6.63)9-10
7.90 (7.19 to 8.68)7.91 (7.20 to 8.69)≥11
Practice level fixed effects
Rurality/remoteness:
1—Primary city
1.19 (1.08 to 1.31)—Urban area
1.14 (1.02 to 1.27)—Accessible area
1.15 (0.97 to 1.36)—Remote area
0.97 (0.85 to 1.11)—Very remote area
List size fourth:
1—512-4675
0.99 (0.88 to 1.11)—4676-7318
0.93 (0.82 to 1.05)—7319-9875
0.85 (0.75 to 0.96)—9876-21 440
Training:
1—Yes
1.10 (1.02 to 1.20)—No
*Practice level data was unavailable for 6 (1.9%) practices with 2139 (1.5%) patients.
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Figure
Cross sectional control chart for observed versus expected number of patients with a high risk prescription. Practices lying
outside 3 SD control limit are statistically significantly different from average
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